Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis Against Kidney Injury

Cryptotanshinone (CPT) was found to suppress postmenopausal osteoporosis by preventing RANKL-mediated osteoclastogenesis and protecting against kidney injury. In a study involving ovariectomized female rats, CPT increased bone mass and bone formation markers while ameliorating kidney injury by reducing BUN and normalizing creatinine levels. In vitro, CPT inhibited osteoclast differentiation by downregulating osteoclast-associated proteins such as cathepsin K, c-Fos, and NFATc1. These findings suggested that CPT had potential clinical applications due to its antiosteoclastogenic and kidney-protective effects.